PrimeRFP SCOUT · Federal Contract Recompete Brief

W58P0521C0008MAB :covid-19: monoclonal antibody therapeutic — Glaxosmithkline LLC

Glaxosmithkline LLC holds $3.0B across 194 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 5 related awards in the incumbent pipeline. The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: NONE. PoP ended May 19, 2022 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

W6qk Acc-Apg Natick

Awarding office

Department of Defense (DOD)

Agency

Glaxosmithkline LLC

Recipient

May 19, 2022

PoP end

$279.9M

Obligated

325412

NAICS

6505

PSC

NONE

Set-aside

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Contract facts

NONE

Contract numberW58P0521C0008

Also listed asW58P05-21-C-0008

AgencyDepartment of Defense (DOD)

Awarding officeW6qk Acc-Apg Natick

IncumbentGlaxosmithkline LLC

UEIFRHTPHMZMX47

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Place of performanceDURHAM, NC

PoP end (current)May 19, 2022

Obligated$279.9M

:COVID-19: MONOCLONAL ANTIBODY (MAB) THERAPEUTIC SOTROVIMAB is a federal NONE award for Department of Defense (DOD) held by Glaxosmithkline LLC. Estimated value $279.9M ($279.9M obligated). Current period of performance ends May 19, 2022. Last award drew 1 bidder. Place of performance: DURHAM, NC.

:COVID-19: MONOCLONAL ANTIBODY (MAB) THERAPEUTIC SOTROVIMAB

Recompete timing

Public

● Past PoP end (1596 days ago)

Current PoP ended May 19, 2022 (1596 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Bonuses end Sept 30

Want the durability read on W58P0521C0008? One Pursuit Analysis, $500, inside 48 business hours.

48 business hours
$500
Credits toward the Pack

Buy one Pursuit Analysis — $500

Incumbent footprint

Public record

Glaxosmithkline LLC — $3.0B obligated across 194 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($3.0B) · all agencies

Department of Health and Human Services (HHS)$3.0B · 100%Department of Defense (DOD)$1.7M · 0%Department of Veterans Affairs (VA)$1.5M · 0%Department of State (DOS)$1.2M · 0%

Open full company profile →

Related awards

Same incumbent

75A50126F61020

TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO IMMUNOGENICITY SUPERIOR…

$493K

Oct 29, 2026

15F06724F0001366

GSK TRAVEL VACCINES

$115K

Dec 31, 2026

15F06726F0000234

GSK VACCINES TERMS AND CONDITIONS REMAIN THE SAME - BPA 15F06722A0000187

$105K

Dec 31, 2026

75A50124F61014

THIS TASK ORDER ESTABLISHES SERVICES FOR H5 PANDEMIC READINESS FOR ACQUISITION OF MEDICAL …

$18.4M

Feb 21, 2027

75A50124F61013

THE PURPOSE OF THIS TASK ORDER IS TO ESTABLISH FILL/FINISH ACTIVITIES FOR ADJUVANT (AS03) …

$15.4M

Feb 21, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract W58P0521C0008?

W58P0521C0008 (MAB :covid-19: monoclonal antibody therapeutic) is a W6qk Acc-Apg Natick award with an estimated value of $279.9M, currently held by Glaxosmithkline LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is W58P05-21-C-0008?

W58P05-21-C-0008 is the dashed form of PIID W58P0521C0008 (MAB :covid-19: monoclonal antibody therapeutic), held by Glaxosmithkline LLC. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded W58P0521C0008?

W6qk Acc-Apg Natick awarded W58P0521C0008 to Glaxosmithkline LLC.

Who is the incumbent on W58P0521C0008?

Glaxosmithkline LLC is the incumbent with $3.0B across 194 related awards in SCOUT’s public footprint. The current period of performance ends May 19, 2022.

When does Glaxosmithkline LLC’s W58P0521C0008 come up for recompete?

SCOUT tracks a period-of-performance end of May 19, 2022. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Want the durability read on W58P0521C0008? One Pursuit Analysis, $500, inside 48 business hours.

One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.

Get the free Exposure Check

No card · under a minute · then the Sprint menu

Buy one Pursuit Analysis — $500

Credits toward the Sprint Pack

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Sep 10, 2026 · refreshed monthlyLatest procurement action Oct 13, 2023